See more : Farmers Bancorp (Frankfort IN) (FABP) Income Statement Analysis – Financial Results
Complete financial analysis of XOMA Corporation (XOMA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of XOMA Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Chow Steel Industries Public Company Limited (CHOW.BK) Income Statement Analysis – Financial Results
- Eurotech S.p.A. (0E7Z.L) Income Statement Analysis – Financial Results
- A.P. Møller – Mærsk A/S (DP4B.DE) Income Statement Analysis – Financial Results
- Landmark Infrastructure Partners LP (LMRKN) Income Statement Analysis – Financial Results
- Prima Moda S.A. (PMA.WA) Income Statement Analysis – Financial Results
XOMA Corporation (XOMA)
About XOMA Corporation
XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.76M | 6.03M | 38.16M | 29.39M | 18.37M | 5.30M | 52.69M | 5.56M | 55.45M | 18.87M | 35.45M | 33.78M | 58.20M | 33.64M | 98.43M | 67.99M | 84.25M | 29.50M | 18.67M | 3.67M | 24.41M | 29.95M | 17.28M | 6.66M | 2.40M | 6.30M | 18.40M | 3.60M | 1.20M | 1.70M | 600.00K | 5.10M | 17.10M | 20.50M | 10.40M | 5.00M | 7.70M | 100.00K | 7.30M |
| Cost of Revenue | 897.00K | 97.00K | 171.00K | 170.00K | 1.25M | 1.68M | 7.88M | 1.40M | 20.70M | 29.47M | 27.36M | 143.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 16.37M | 0.00 | 0.00 | 0.00 | 1.87M | -1.20M | -1.60M | -2.00M | -2.10M | -2.90M | -3.30M | -2.60M | -800.00K | 6.50M | 5.60M | 24.20M | 14.50M | -1.40M | 41.40M | 8.50M |
| Gross Profit | 3.86M | 5.93M | 37.99M | 29.22M | 17.12M | 3.62M | 44.82M | 4.16M | 34.75M | -10.60M | 8.09M | 33.64M | 58.20M | 33.64M | 98.43M | 67.99M | 84.25M | 29.50M | 18.67M | -12.71M | 24.41M | 29.95M | 17.28M | 4.79M | 3.60M | 7.90M | 20.40M | 5.70M | 4.10M | 5.00M | 3.20M | 5.90M | 10.60M | 14.90M | -13.80M | -9.50M | 9.10M | -41.30M | -1.20M |
| Gross Profit Ratio | 81.15% | 98.39% | 99.55% | 99.42% | 93.18% | 68.26% | 85.05% | 74.84% | 62.67% | -56.19% | 22.82% | 99.58% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | -346.74% | 100.00% | 100.00% | 100.00% | 71.93% | 150.00% | 125.40% | 110.87% | 158.33% | 341.67% | 294.12% | 533.33% | 115.69% | 61.99% | 72.68% | -132.69% | -190.00% | 118.18% | -41,300.00% | -16.44% |
| Research & Development | 143.00K | 153.00K | 171.00K | 170.00K | 1.25M | 1.68M | 7.88M | 44.23M | 70.85M | 80.75M | 74.85M | 68.32M | 68.14M | 77.41M | 58.13M | 82.58M | 66.22M | 52.09M | 39.90M | 49.78M | 57.46M | 42.62M | 35.93M | 30.01M | 41.50M | 43.80M | 29.90M | 26.40M | 22.10M | 27.30M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 25.61M | 23.19M | 20.46M | 16.80M | 21.00M | 18.56M | 24.34M | 18.32M | 20.62M | 19.87M | 18.48M | 16.87M | 24.01M | 23.25M | 23.74M | 24.15M | 20.58M | 18.09M | 14.80M | 31.98M | 24.49M | 19.41M | 8.68M | 6.07M | 6.10M | 5.40M | 5.60M | 5.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 25.61M | 23.19M | 20.46M | 16.80M | 21.00M | 18.56M | 24.34M | 18.32M | 20.62M | 19.87M | 18.48M | 16.87M | 24.01M | 23.25M | 23.74M | 24.15M | 20.58M | 18.09M | 14.80M | 31.98M | 24.49M | 19.41M | 8.68M | 6.07M | 6.10M | 5.40M | 5.60M | 5.50M | 5.40M | 8.70M | 35.10M | 41.80M | 49.90M | 37.80M | 7.50M | 3.90M | 13.00M | 4.00M | 3.00M |
| Other Expenses | 20.71M | 97.00K | -879.00K | 1.23M | 3.82M | 4.34M | 1.12M | 1.51M | 44.00K | -31.00K | -197.00K | -956.00K | 0.00 | 82.00K | 3.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.87M | 1.20M | 1.60M | 2.00M | 2.10M | 2.90M | 3.30M | 2.80M | 3.00M | 2.00M | 1.80M | 1.40M | 800.00K | 1.40M | 2.00M | 1.40M |
| Operating Expenses | 46.46M | 23.44M | 20.63M | 16.97M | 22.26M | 20.25M | 32.21M | 62.56M | 91.47M | 100.61M | 93.33M | 85.19M | 92.15M | 100.66M | 81.87M | 106.72M | 86.80M | 70.18M | 54.69M | 81.76M | 81.95M | 62.03M | 44.61M | 34.21M | 48.80M | 50.80M | 37.50M | 34.00M | 30.40M | 39.30M | 37.90M | 44.80M | 51.90M | 39.60M | 8.90M | 4.70M | 14.40M | 6.00M | 4.40M |
| Cost & Expenses | 46.61M | 23.44M | 20.63M | 16.97M | 22.26M | 20.25M | 32.21M | 62.56M | 91.47M | 100.61M | 93.33M | 85.33M | 92.15M | 100.66M | 81.87M | 106.72M | 86.80M | 70.18M | 54.69M | 81.76M | 81.95M | 62.03M | 44.61M | 36.08M | 47.60M | 49.20M | 35.50M | 31.90M | 27.50M | 36.00M | 35.30M | 44.00M | 58.40M | 45.20M | 33.10M | 19.20M | 13.00M | 47.40M | 12.90M |
| Interest Income | 0.00 | 0.00 | 35.00K | 159.00K | 1.05M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 16.00K | 49.00K | 859.00K | 0.00 | 1.68M | 1.88M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 569.00K | 0.00 | 461.00K | 1.84M | 1.92M | 922.00K | 1.24M | 3.95M | 4.18M | 4.28M | 4.63M | 4.34M | 2.46M | 385.00K | 4.89M | 7.00M | 0.00 | 12.93M | 4.25M | 0.00 | 1.88M | 0.00 | 0.00 | 2.68M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 900.00K | 274.00K | 167.00K | 172.00K | 1.92M | 30.00K | 304.00K | 769.00K | 1.53M | 1.86M | 2.58M | 4.12M | 5.36M | 5.72M | 6.83M | 8.12M | 6.73M | 6.17M | 5.77M | 4.55M | 3.99M | 2.12M | 1.25M | -1.87M | 1.20M | 1.60M | 2.00M | 2.10M | 2.90M | 3.30M | 2.80M | 3.00M | 2.00M | 1.80M | 1.40M | 800.00K | 1.40M | 2.00M | 1.40M |
| EBITDA | -39.36M | -16.85M | 16.52M | 13.81M | 1.85M | -12.49M | 20.78M | -48.82M | -15.31M | -32.14M | -116.87M | -62.63M | -24.91M | -62.62M | 18.00M | -31.91M | 4.19M | -34.51M | -36.03M | -73.16M | -53.55M | -29.96M | -26.08M | -31.29M | -44.00M | -41.30M | -15.20M | -26.20M | -23.40M | -31.00M | -31.90M | -35.90M | -39.30M | -22.90M | -21.30M | -13.40M | -3.90M | -45.30M | -4.20M |
| EBITDA Ratio | -827.28% | -282.31% | 43.63% | 46.42% | -0.34% | -200.19% | 40.98% | -997.16% | -62.15% | -423.76% | -163.81% | -143.35% | -49.14% | -182.17% | 23.82% | -44.89% | 5.05% | -117.34% | -382.61% | -2,017.08% | -222.46% | -102.94% | -162.25% | -510.12% | -1,883.33% | -552.38% | -89.67% | -702.78% | -2,266.67% | -1,805.88% | -5,916.67% | -549.02% | -281.29% | -145.37% | -290.38% | -344.00% | -57.14% | -47,200.00% | -68.49% |
| Operating Income | -41.85M | -17.41M | 17.53M | 12.42M | -3.89M | -16.86M | 17.03M | -61.56M | -39.72M | -81.83M | -58.21M | -56.62M | -33.96M | -67.10M | 12.96M | -38.73M | -2.54M | -40.68M | -36.03M | -78.10M | -57.54M | -32.08M | -27.33M | -29.42M | -45.20M | -42.90M | -17.10M | -28.30M | -26.30M | -34.30M | -34.70M | -38.90M | -41.30M | -24.70M | -22.70M | -14.20M | -5.30M | -47.30M | -5.60M |
| Operating Income Ratio | -879.53% | -288.93% | 45.94% | 42.25% | -21.15% | -318.12% | 32.32% | -1,106.36% | -71.64% | -433.75% | -164.18% | -167.62% | -58.35% | -199.47% | 13.17% | -56.97% | -3.02% | -137.92% | -192.97% | -2,130.86% | -235.70% | -107.11% | -158.17% | -441.75% | -1,883.33% | -680.95% | -92.93% | -786.11% | -2,191.67% | -2,017.65% | -5,783.33% | -762.75% | -241.52% | -120.49% | -218.27% | -284.00% | -68.83% | -47,300.00% | -76.71% |
| Total Other Income/Expenses | 1.02M | 295.00K | -1.64M | -619.00K | 1.90M | 3.42M | -773.00K | 8.03M | 19.12M | 43.53M | -65.87M | -14.52M | 1.23M | -1.63M | -6.68M | -6.89M | -9.78M | -11.16M | 38.81M | -846.00K | -1.12M | 871.00K | 1.96M | 2.68M | 1.20M | -6.50M | 1.50M | -900.00K | 3.80M | -300.00K | 3.60M | -7.90M | 8.80M | 6.90M | 8.90M | 3.80M | 500.00K | 1.90M | 800.00K |
| Income Before Tax | -40.83M | -17.12M | 15.89M | 11.80M | -1.98M | -13.44M | 16.26M | -53.53M | -20.61M | -38.30M | -124.07M | -71.14M | -32.73M | -68.73M | 6.28M | -45.63M | -12.33M | -51.84M | 2.78M | -78.94M | -58.65M | -31.21M | -25.37M | -26.73M | -44.00M | -49.40M | -15.70M | -29.20M | -22.50M | -34.60M | -31.10M | -46.80M | -32.50M | -17.80M | -13.80M | -10.40M | -4.80M | -45.40M | -4.80M |
| Income Before Tax Ratio | -858.15% | -284.04% | 41.64% | 40.15% | -10.79% | -253.65% | 30.86% | -962.08% | -37.16% | -203.02% | -349.98% | -210.58% | -56.24% | -204.30% | 6.38% | -67.11% | -14.63% | -175.74% | 14.90% | -2,153.94% | -240.26% | -104.20% | -146.84% | -401.44% | -1,833.33% | -784.13% | -85.33% | -811.11% | -1,875.00% | -2,035.29% | -5,183.33% | -917.65% | -190.06% | -86.83% | -132.69% | -208.00% | -62.34% | -45,400.00% | -65.75% |
| Income Tax Expense | 0.00 | -15.00K | 91.00K | -1.50M | 5.72M | -98.00K | 1.66M | 4.69M | 4.23M | 4.25M | -14.00K | -74.00K | 15.00K | 27.00K | 5.73M | -383.00K | 9.78M | 11.16M | 3.00K | 846.00K | 1.12M | 1.17M | 709.00K | -4.00K | 600.00K | 4.30M | -1.30M | 800.00K | -3.80M | 300.00K | -3.40M | 8.20M | -7.00M | -1.00M | -3.80M | -2.20M | -500.00K | -600.00K | -800.00K |
| Net Income | -40.83M | -17.10M | 15.80M | 13.30M | -7.70M | -13.34M | 14.60M | -53.53M | -20.61M | -38.30M | -124.06M | -71.07M | -32.74M | -68.76M | 550.00K | -45.25M | -12.33M | -51.84M | 2.78M | -78.94M | -58.65M | -33.25M | -28.04M | -29.41M | -45.80M | -47.20M | -15.80M | -29.10M | -22.50M | -34.60M | -31.30M | -47.10M | -34.30M | -23.70M | -18.90M | -12.00M | -4.80M | -46.70M | -4.80M |
| Net Income Ratio | -858.15% | -283.79% | 41.40% | 45.25% | -41.91% | -251.80% | 27.70% | -962.08% | -37.16% | -203.02% | -349.94% | -210.36% | -56.26% | -204.38% | 0.56% | -66.55% | -14.63% | -175.74% | 14.89% | -2,153.94% | -240.26% | -111.01% | -162.28% | -441.69% | -1,908.33% | -749.21% | -85.87% | -808.33% | -1,875.00% | -2,035.29% | -5,216.67% | -923.53% | -200.58% | -115.61% | -181.73% | -240.00% | -62.34% | -46,700.00% | -65.75% |
| EPS | -4.04 | -1.50 | 1.40 | 1.25 | -0.88 | -1.59 | 0.75 | -8.89 | -3.50 | -7.13 | -28.60 | -22.00 | -20.73 | -73.88 | 1.00 | -102.11 | -28.90 | -162.07 | 9.00 | -279.09 | -234.39 | -141.77 | -123.42 | -136.34 | -260.70 | -330.11 | -119.86 | -268.67 | -285.16 | -474.00 | -438.00 | -660.00 | -531.00 | -504.00 | -429.00 | -336.00 | -165.06 | -1.91K | -171.00 |
| EPS Diluted | -4.04 | -1.50 | 1.30 | 1.16 | -0.88 | -1.59 | 0.73 | -8.89 | -3.50 | -6.64 | -28.54 | -21.99 | -20.73 | -73.88 | 0.97 | -102.11 | -28.90 | -162.07 | 9.00 | -279.09 | -234.39 | -141.77 | -123.42 | -136.34 | -260.70 | -330.11 | -119.86 | -268.67 | -285.16 | -474.00 | -438.00 | -660.00 | -531.00 | -504.00 | -429.00 | -336.00 | -165.06 | -1.91K | -171.00 |
| Weighted Avg Shares Out | 11.47M | 11.41M | 11.29M | 10.67M | 8.76M | 8.37M | 7.62M | 6.02M | 5.89M | 5.37M | 4.34M | 3.23M | 1.58M | 930.65K | 549.65K | 443.10K | 426.49K | 319.87K | 287.14K | 282.86K | 250.23K | 234.52K | 227.20K | 215.73K | 175.68K | 142.98K | 131.82K | 108.31K | 78.90K | 73.00K | 71.46K | 71.36K | 64.60K | 47.02K | 44.06K | 35.71K | 29.08K | 24.48K | 28.07K |
| Weighted Avg Shares Out (Dil) | 11.47M | 11.41M | 12.19M | 11.50M | 8.76M | 8.37M | 7.98M | 6.02M | 5.89M | 5.77M | 4.35M | 3.23M | 1.58M | 930.65K | 565.65K | 443.10K | 426.49K | 319.87K | 300.21K | 282.86K | 250.23K | 234.52K | 227.20K | 215.73K | 175.68K | 142.98K | 131.82K | 108.31K | 78.90K | 73.00K | 71.46K | 71.36K | 64.60K | 47.02K | 44.06K | 35.71K | 29.08K | 24.48K | 28.07K |
XOMA to Present at H.C. Wainwright Global Investment Conference
EMERYVILLE, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator playing a distinctive role in helping companies achieve their goal of improving human health, announced today its Chairman and Chief Executive Officer, Jim Neal,...
XOMA: First Steps Towards Greatness
While XOMA offers an investment into an important sector of healthcare, drug revenue royalties, the story is just beginning. From first glance, years of losses and flat revenues look poor, but something special is hidden underneath.
Xoma (XOMA) Reports Q1 Loss, Misses Revenue Estimates
Xoma (XOMA) delivered earnings and revenue surprises of 5.88% and 12.73%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
XOMA to Present at Oppenheimer's 32nd Annual Healthcare Conference
EMERYVILLE, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator playing a distinctive role in helping companies achieve their goal of improving human health, announced today its Chairman and Chief Executive Officer, Jim Neal,...
XOMA to Present at the 42nd Annual Cowen Health Care Conference
EMERYVILLE, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator playing a distinctive role in helping companies achieve their goal of improving human health, announced today its Chairman and Chief Executive Officer, Jim Neal,...
XOMA to Present at Aegis Capital Corp Investor Conference
EMERYVILLE, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator playing a distinctive role in helping companies achieve their goal of improving human health, announced today its Chief Executive Officer, Jim Neal, will present...
XOMA to Present at Upcoming Investor Conferences
EMERYVILLE, Calif., Dec. 21, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator playing a distinctive role in helping companies achieve their goal of improving human health, announced today its Chief Executive Officer, Jim Neal, will present...
NEXE Innovations says its XOMA Superfoods line to list on e-commerce retailer platform Walmart.ca
NEXE Innovations Inc (TSX-V:NEXE, OTC:NEXNF)., a leader in plant-based materials manufacturing, has revealed that its popular XOMA Superfoods product line is now approved for listing with leading Canadian e-commerce retailer Walmart.ca.
Strength Seen in Xoma (XOMA): Can Its 11.2% Jump Turn into More Strength?
Xoma (XOMA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
XOMA to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
EMERYVILLE, Calif., Sept. 22, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA)'s Chief Executive Officer, Jim Neal, will present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference on Tuesday, September 28, 2021, at 10:20 AM PT.
Source: https://incomestatements.info
Category: Stock Reports
What were XOMA’s total revenues in 2023?
XOMA recorded total revenues of $1.8 million and $4.8 million for the fourth quarter and full year of 2023, respectively.